Document:

<PAGE>   1

                                                                    EXHIBIT 10.1

                                LICENSE AGREEMENT

        This Agreement is made effective this 6th day of September, 2000, by and
between Temple University - Of The Commonwealth System of Higher Education, a
corporation organized and existing under the laws of the Commonwealth of
Pennsylvania, having a principal place of business at Broad Street and
Montgomery Avenue, Philadelphia, Pennsylvania and Nutraceutix, Inc., a
corporation organized and existing under the laws of the State of Delaware,
having a principal place of business at 8340 - 154th Avenue N.E., Redmond,
Washington 98052.

        WHEREAS, Temple University - Of The Commonwealth System of Higher
Education is the owner of the entire interest in United States Patent
Application 09/037,096 and PCT Application PCT/US99/04508; and

        WHEREAS, Nutraceutix, Inc., desires to obtain an exclusive worldwide
license under the aforementioned patent applications, patents and technical
information related thereto, for application thereof to dietary supplements and
pharmaceutical products, including over-the-counter products, prescription
drugs, OTC drugs and generic drugs;

        NOW, THEREFORE, in consideration of the premises and of the covenants
and obligations hereinafter set forth, and intending to be legally bound, the
parties hereby agree as follows:

1.      DEFINITIONS

The following definitions shall apply throughout this Agreement:

        1.1 "AFFILIATE" shall mean each and every business entity controlling,
controlled by or under common control with COMPANY for the purposes of
manufacture, use or sale of LICENSED PRODUCT. For purposes of this definition,
"control" shall mean ownership, directly or indirectly, of at least fifty
percent (50%) of the voting stock.

        1.2 "ANNIVERSARY" shall mean an anniversary of the EFFECTIVE DATE.

        1.3 "COMPANY" shall mean Nutraceutix, Inc., and its AFFILIATES.

        1.4 "CONFIDENTIAL INFORMATION" shall mean all information disclosed or
samples supplied by one party to the other pursuant to this Agreement. However,
CONFIDENTIAL INFORMATION shall not include information which: (i) was known to
the receiving party prior to the date of disclosure by the disclosing party or
is developed independently of information received from the disclosing party by
those who have not had access to this information; or (ii) is lawfully received
in good faith at any time by the receiving party from others lawfully in
possession of the same and having the right to disclose the same; or (iii) is,
as of the date of receipt, in the public domain or subsequently enters the
public domain other than by reason or omissions of the receiving party; or (iv)
is required to be disclosed by law, rule of court or regulation.

        1.5 "EFFECTIVE DATE" shall mean the date first above written as the
effective date of this Agreement.

        1.6 "INVENTOR" shall mean Reza Fassihi of the TEMPLE faculty.

                                       12
<PAGE>   2

        1.7 "LICENSED PRODUCT" shall mean any PRODUCT the manufacture, use or
sale of which would infringe, induce infringement of, or contribute to the
infringement of at least one VALID CLAIM contained in a patent application
included in PATENT RIGHTS if that VALID CLAIM were contained, instead, in an
issued patent not included in PATENT RIGHTS.

        1.8 "NET SALES" shall mean the gross receipts from the SALE of LICENSED
PRODUCT by COMPANY or by its sublicensees less deductions for: (i)
transportation charges, including insurances, sales and excise taxes and duties
paid; (ii) normal and customary trade, quantity and cash discounts allowed;
(iii) sales commissions; and (iv) allowances on account of rejection or return
by customers.

        1.9 "PATENT RIGHTS" shall mean United States Patent Application
09/037,096 and PCT application PCT/US99/04508, and any foreign counterparts
thereof, or any continuations, continuations-in-part, divisions, re-issues,
additions, renewals or extensions thereof and any patents issued therefrom.

        1.10 "PRODUCT" shall mean: (i) any dietary supplement (as defined in the
1994 Dietary Supplement and Health Education Act)(referred to herein as a
"SUPPLEMENT"); (ii) any drug which can be purchased by the general public
without a prescription (referred to herein as "OTC DRUG"); and (iii) any
prescription drug (whether existing at the time of this Agreement or yet to be
discovered). If any item which is classified on the date of this Agreement as a
SUPPLEMENT, an OTC DRUG or a prescription drug, is subsequently reclassified
otherwise, such item shall nevertheless remain a SUPPLEMENT, an OTC DRUG or a
prescription drug (as the case may be) for all purposes under this Agreement.

        1.11 "SALE" shall mean any transaction for which consideration is
received for the sale, lease, license, transfer or other disposition of LICENSED
PRODUCT by COMPANY or by its sublicensees.

        1.12 "TECHNICAL INFORMATION" shall mean any CONFIDENTIAL INFORMATION of
a technical nature relating to LICENSED PRODUCT, which is in the possession of
TEMPLE as of the effective date of this Agreement, and which is necessary or
useful to COMPANY in furtherance of the development, manufacture or marketing of
LICENSED PRODUCT.

        1.13 "TEMPLE" shall mean Temple University - Of the Commonwealth System
of Higher Education.

        1.14 "VALID CLAIM" shall mean a claim of a patent application or patent,
which claim has not expired and has not been held unenforceable, unpatentable or
invalid by unappealable decision of a court or other governmental agency of
competent jurisdiction.

2.      CONFIDENTIALITY

        2.1 CONFIDENTIAL INFORMATION disclosed in documentary form shall be
marked "Confidential". Oral discussions of CONFIDENTIAL INFORMATION shall be
reduced to writing by the disclosing party and a copy marked "Confidential"
provided to the receiving party within thirty (30) days of the disclosure date.

        2.2 The receiving party shall hold all CONFIDENTIAL INFORMATION in
strict confidence for a period of five (5) years from the disclosure date; not
use said CONFIDENTIAL INFORMATION except as provided in this Agreement; and not
disclose, directly or indirectly, said CONFIDENTIAL INFORMATION to others except
with the prior written consent of the disclosing party.

                                       13
<PAGE>   3

        2.3 The receiving party shall, upon request by the disclosing party,
promptly return all written materials or samples of tangible property received
hereunder, as well as all summaries thereof and notes pertaining thereto, with
the exception that one copy of said written materials may be retained by the
receiving party solely for archival purposes.

        2.4 Notwithstanding any other provision of this Agreement, it is
recognized by COMPANY that TEMPLE, through the INVENTOR, shall have the right to
publish the results of research concerning LICENSED PRODUCT. However, TEMPLE and
the INVENTOR agree to notify COMPANY in writing of any such proposed publication
ninety (90) days before submission. COMPANY may request deletion of sensitive
information from the proposed publication, and TEMPLE agrees to give good faith
consideration to such a request.

        2.5 The parties shall keep the financial terms of this Agreement set
forth in Section 4 confidential, except to the extent disclosure thereof may be
required by applicable securities laws or otherwise by law. The parties shall be
free to disclose to third parties the existence of this Agreement and the
nonfinancial terms of this Agreement.

        2.6 Promptly after the execution of this Agreement, TEMPLE shall
delivery all currently existing TECHNICAL INFORMATION to COMPANY. Thereafter
TEMPLE shall deliver to COMPANY all additional TECHNICAL INFORMATION promptly
after it is developed or obtained by TEMPLE. In addition, TEMPLE shall deliver
to COMPANY from time to time other data, materials and information relating to
the LICENSED PATENT which it develops or obtains and which is necessary or
useful to COMPANY in furtherance of the development, manufacture or marketing of
LICENSED PRODUCT.

3.      GRANT OF LICENSE

        3.1 TEMPLE grants to COMPANY a world-wide exclusive license under PATENT
RIGHTS and TECHNICAL INFORMATION, with the right to grant sublicensees, to make,
have made, use, sell, offer for sale, export, import and otherwise deal with
LICENSED PRODUCT. This license shall be perpetual unless and until terminated,
in whole or in part, in accordance with the provisions of this Agreement.

        3.2 Notwithstanding the preceding license grant, TEMPLE shall retain
rights to make, have made, use and import LICENSED PRODUCT royalty-free for
non-commercial educational and research purposes only, and shall be free to
grant these rights to other non-profit educational and research institutions.

        3.3 The parties acknowledge that inventions in PATENT RIGHTS may have
resulted from United States Government funding, and agree that their rights and
obligations under this Agreement shall be subject to TEMPLE's obligations to the
United States Government, if any, which arise out of the receipt by TEMPLE of
research funding from the United States Government. In particular, COMPANY
agrees that LICENSED PRODUCT sold in the United States under this Agreement
shall be manufactured substantially in the United States.

4.      PAYMENTS

        4.1 In consideration of the license granted to COMPANY under the terms
of this Agreement, COMPANY shall pay to TEMPLE royalties as follows:

                                       14
<PAGE>   4

               (a) a royalty of thirty cents ($.30) for each one thousand
(1,000) tablets of LICENSED PRODUCT which is a SUPPLEMENT and which is sold by
COMPANY or by its sublicensees; and

               (b) a royalty of forty-five cents ($.45) for each one thousand
(1,000) tablets of LICENSED PRODUCT which is an OTC DRUG which is sold by
COMPANY or by its sublicensees; and

               (c) a royalty equal to four percent (4%) of NET SALES of any
LICENSED PRODUCT which is a prescription drug and which is sold by COMPANY or by
its sublicensees.

        4.2 In further consideration of the license granted to COMPANY under the
terms of this Agreement, COMPANY shall pay to TEMPLE, within thirty (30) days
after the EFFECTIVE DATE, a non-refundable license fee of fifty thousand dollars
($50,000.00), which license fee payment shall not be creditable against any
other payments due to TEMPLE under this Agreement.

        4.3 In further consideration of the license granted to COMPANY under the
terms of this Agreement, COMPANY shall pay to TEMPLE, within thirty (30) days of
the first ANNIVERSARY and annually thereafter, a non-refundable license
maintenance fee regardless of or irrespective of actual NET SALES, which license
maintenance fee payment may be credited against payments due to TEMPLE under
Paragraph 4.1 during the same calendar year, with no carry-over of unused credit
to subsequent calendar years. The amount of the license maintenance fee payment
shall be twenty-five thousand dollars ($25,000.00), no more than one-half (1/2)
of which may be credited against payments due to TEMPLE under Sub-Paragraphs
4.1(a) and 4.1(b) pertaining to SUPPLEMENTS and OTC DRUGS, and no more than
one-half (1/2) of which may be credited against payments due to TEMPLE under
Sub-Paragraphs 4.1(c) pertaining to prescription drugs.

        4.4 In further consideration of the license granted to COMPANY under the
terms of this Agreement, COMPANY shall pay TEMPLE a royalty equal to fifty
percent (50%) of any license fee or similar payment received by COMPANY from any
sublicensee under the LICENSE in consideration of entering into such sublicense,
not including: (i) any royalty or fee received by COMPANY on account of SALES of
LICENSED PRODUCTS or (ii) any payment received by COMPANY as reimbursement for
research and/or development costs; provided that, after payment of the first
royalty pursuant to this Paragraph 4.4, each subsequent royalty pursuant to this
Paragraph 4.4 shall be reduced by an amount equal to COMPANY'S reasonable,
unreimbursed, out-of-pocket research and/or development costs incurred in
connection with developing Licensed Products, which costs include, and are not
limited to: (i) cost of formulation development, (ii) purchase price of raw
materials, including active ingredients, for formulation development, (iii)
labor costs for research and/or development of a Licensed Product, (iv) cost of
research and development compliance and documentation for the U.S. Food and Drug
Administration or similar governmental agencies, (v) cost of creating pilot
batches for bench testing (i.e., for testing friability, hardness, blend
uniformity, etc.), (vi) cost of dissolution testing, (vii) cost of pilot
stability testing according to ICH guidelines, (viii) cost of development and
validation of analytic methods, (ix) cost of development of master formulation
documentation, (x) cost of development of indented bill of materials, (xi) cost
of vendor certification for all raw materials, (xii) cost of cGMP audits of
manufacturing sites, (xiii) cost of bioequivalence and clinical trials, (xiv)
cost of preparing technical files for sale or license to a pharmaceutical
licensee and (xv) costs incurred for subcontractors involved in developing
Licensed Products.

        4.5 Royalty payments pursuant to Paragraph 4.1 for SALES in each country
will commence with the first unit of LICENSED PRODUCT sold by COMPANY or by its
sublicensees in such country

                                       15
<PAGE>   5

and will end coincident with the expiration date of the last-to-expire issued
patent within PATENT RIGHTS in such country covering such LICENSED PRODUCT.

5.      STATEMENTS AND REMITTANCES

        5.1 COMPANY shall keep and shall require its sublicensees to keep
complete and adequate records relating to the manufacture and SALE of LICENSED
PRODUCT.

        5.2 Within sixty (60) days after the close of each calendar quarter,
COMPANY shall remit to TEMPLE a statement of NET SALES by COMPANY and by its
sublicensees on account for such quarter, which statement shall be accompanied
by the payment due to TEMPLE pursuant to Paragraph 4.1 on account of NET SALES
for such quarter.

        5.3 COMPANY shall use commercially reasonable efforts to obtain from
each of its sublicensees verified, and if available audited, financial
statements setting forth the amount of sales of LICENSED PRODUCT by each such
sublicensee ("Sublicensee Reports"). The financial statements of COMPANY and the
Sublicensee Reports will be audited annually by an independent certified public
accountant. TEMPLE shall have the right to employ, at its own expense, a
qualified accountant of its own selection to whom COMPANY shall make no
unreasonable objection, to examine the Sublicensee Reports and the books and
records of COMPANY relating to sales of LICENSED PRODUCT by COMPANY for the
purpose of verifying the amount of royalty payments due. Such examination of the
Sublicensee Reports and the books and records of COMPANY shall take place during
regular business hours during the term of this Agreement and for two (2) years
after its termination; provided, however, that such an examination shall not
take place more than once a year and shall not cover records for more than the
preceding three (3) years, and provided that such accountant shall report to
TEMPLE only as to the accuracy of the royalty statements and payments. If such
accountant shall find an underpayment to TEMPLE, presentation of a written
statement substantiating the underpayment will be provided to COMPANY. If the
discrepancy relates to information contained in a Sublicensee Report, COMPANY
shall use commercially reasonable efforts to arrange for an audit of subject
sublicensee by TEMPLE. If COMPANY is not in agreement with the findings of the
qualified accountant selected by TEMPLE, then COMPANY shall so notify TEMPLE in
writing within thirty (30) days of receipt by COMPANY of said findings (or in
the case of an audit of a sublicensee, within thirty (30) days of receipt by
COMPANY of the findings regarding the audit of the sublicensee), in which case
the parties will jointly appoint, within a further period of thirty (30) days,
an independent qualified accountant to validate, at COMPANY's expense, TEMPLE's
accountant's findings, and the decision of said independent account shall be
final. If said independent accountant verifies that an underpayment has
occurred, the amount due and interest (accruing at the prevailing Prime Rate
from the date payment was due through the date of actual payment to TEMPLE)
shall be paid to TEMPLE within thirty (30) days. Should such underpayment
represent more than five percent (5%) of the royalties due TEMPLE, COMPANY shall
reimburse TEMPLE for the cost of the examination by TEMPLE's accountant which
disclosed such underpayment.

        5.4 All payments due to TEMPLE under this Agreement shall be made in
United States dollars and shall be sent by COMPANY to TEMPLE to the attention of
"Business Manager" at the address shown in Paragraph 13.5. However, TEMPLE shall
have the right, upon giving written notice to COMPANY, to receive royalty
payments within a particular country in the local currency if permitted by law.

        5.5 If COMPANY fails to make any payment due to TEMPLE within the time
prescribed by the terms of this Agreement, a penalty equal to one percent (1%)
of the amount due and unpaid on the first day of each calendar month shall be
added to the amount due. However, the provisions of this

                                       16
<PAGE>   6

Paragraph 5.5 shall not apply to any underpayment of royalties which is
uncovered by an audit of the books of COMPANY or of its sublicensees pursuant to
Paragraph 5.2.

6.      REPRESENTATIONS

        6.1 TEMPLE represents that it has the right to enter into this Agreement
and to make the herein grant of license under PATENT RIGHTS and TECHNICAL
INFORMATION. TEMPLE further represents that it is the sole and exclusive owner
of PATENT RIGHTS and TECHNICAL INFORMATION, all of which are free and clear of
any lien, charges and encumbrances.

        6.2 TEMPLE makes no warranty that exercise by COMPANY or its
sublicensees of the rights granted herein will not infringe any patents owned by
a third party, or that any patent application within PATENT RIGHTS will issue as
a patent.

        6.3 COMPANY warrants that, prior to the execution of this Agreement, it
has not negotiated or in any manner discussed, whether formally or informally,
with any third party any agreement or other arrangement, including but not
limited to research or consulting agreements, which provides for any portion of
the amounts payable to TEMPLE pursuant to Section 4 of this Agreement, or any
consideration which would reduce the amounts payable to TEMPLE pursuant to
Section 4 of this Agreement, to be paid in any form, including but not limited
to amounts of money or shares of stock, to any INVENTOR, any INVENTOR's spouse
or other relative, or any entity in which any of them has a financial interest.

7.      PATENT PROSECUTION AND LITIGATION

        7.1 TEMPLE, in consultation with COMPANY but in TEMPLE's sole
discretion, shall diligently prosecute all patent applications and maintain all
patents within PATENT RIGHTS, to the extent permitted by law, in all countries
designated in writing by COMPANY during the term of this Agreement. Except as
provided in Paragraph 7.3, COMPANY shall be responsible for all costs and
expenses incurred by TEMPLE, both prior to and during the term of this
Agreement, in the preparation, filing and prosecution of all patent applications
within PATENT RIGHTS, and in the maintenance of all patents with PATENT RIGHTS.
Such costs and expenses shall not be creditable against any other payments due
to TEMPLE under this Agreement.

        7.2 COMPANY shall make all payments due to TEMPLE pursuant to Paragraph
7.1 within thirty (30) days of receipt of detailed invoices therefore supported
by copies of the subject receipts and invoices or such other supporting
documentation as COMPANY may reasonably request. TEMPLE, in its sole discretion,
may elect to have its patent counsel submit such invoices directly to COMPANY,
in which case COMPANY shall pay TEMPLE's patent counsel directly.

        7.3 In the event COMPANY notifies TEMPLE in writing that it will stop
paying the costs and expenses with respect to any patent application or patent
in any country, TEMPLE, at its option, may assume the obligation of supporting
such patent application or patent in such country, and COMPANY's rights and
obligations thereto under this Agreement shall terminate in such country.
Termination of COMPANY's rights and obligations with respect to any patent
application or patent in any country shall in no way affect the rights and
obligations of COMPANY to the same patent application or patent in any other
country.

        7.4 TEMPLE may file patent applications in countries other than those
designated by COMPANY; provided, however, that TEMPLE shall notify COMPANY in
writing of any such filing within thirty (30) days of the filing date. If,
within thirty (30) days of its receipt of such notification, COMPANY fails to
inform TEMPLE in writing that it wishes to support such applications in such

                                       17
<PAGE>   7

countries, TEMPLE shall bear all the costs associated with such additional
patent application filings, and such applications in such countries and any
patents granting therefrom shall not be included within PATENT RIGHTS. TEMPLE
shall then be free to license such patents and patent applications in such
countries to others.

        7.5 COMPANY, at is option, may defend any claim, made by others, of
patent infringement resulting from the manufacture, use, sale or other
disposition of LICENSED PRODUCT, whether such claim shall be made against TEMPLE
or COMPANY, and if COMPANY defends such claim, COMPANY shall bear all costs and
expenses, including reasonable attorneys' fees, incurred in connection with any
such claim. These costs and expenses will be a credit against fifty percent
(50%) of royalty payments due to TEMPLE on account of NET SALES of said LICENSED
PRODUCT, pursuant to Paragraph 4.1, in each year during the term of this
Agreement until fully offset. Each party to this Agreement agrees that it shall
notify the other party in writing in the event any claim of infringement is made
against that party.

        7.6 In the event either party becomes aware of any actual or threatened
infringement of PATENT RIGHTS in any country, that party shall promptly notify
the other party in writing. COMPANY shall have the first right to bring an
infringement action against the infringer and to use TEMPLE's name if legally
required in connection therewith. If COMPANY does not proceed with a particular
patent infringement action or attempt to sublicense the infringer within ninety
(90) days of notification, TEMPLE, after notifying COMPANY in writing, shall be
entitled to proceed against such infringement at its own expense, through
counsel of its choice. The party conducting such suit shall have full control
over its conduct. In any event, TEMPLE and COMPANY shall assist one another and
cooperate in any such litigation. TEMPLE and COMPANY may also jointly
participate in any infringement action if both parties agree to do so in writing
in advance, and set forth the basis for sharing of expenses.

        7.7 The amount of any recovery resulting from any litigation to enforce
the PATENT RIGHTS or settlement thereof ("Recovery") shall first satisfy the
attorneys' fees and costs incurred by the enforcing party in such litigation
("Fees and Costs"); provided, however, that, if COMPANY is the enforcing party
and a royalty reduction was applied pursuant to Paragraph 7.5 ("Royalty
Reduction"), then TEMPLE shall receive from the Recovery an amount calculated by
dividing the Royalty Reduction by the Fees and Costs and multiplying the result
by the Recovery. Any Recovery in excess of Fees and Costs shall first satisfy
royalty payments due to TEMPLE, with any remaining balance to the enforcing
party. Each party shall always have the right to be represented by counsel of
its choice and at its own expense in any suit instituted by another for
infringement. If the parties have agreed to participate jointly in an
infringement action, any recovery in excess of satisfying the parties' attorney
fees, costs of the litigation and payment of the royalty due to TEMPLE on
account of the infringement, shall be allocated to the parties in the same
proportion as the sharing of the litigation expenses.

8.      INDEMNIFICATION

        8.1 COMPANY agrees to indemnify, hold harmless, and defend TEMPLE, its
trustees, officers, employees and agents against any and all claims, excluding
claims stemming from TEMPLE's use of LICENSED PRODUCT as outlined in Paragraph
3.2, including fees and costs arising out of the exercise of any rights granted
under this Agreement, without limiting the generality of the foregoing, against
any damages, losses or liabilities whatsoever including but not limited to death
or injury to person or damage to property arising from the commercial sale and
clinical research of LICENSED PRODUCT by COMPANY, its sublicensees or any
customers of any of them in any manner whatsoever. TEMPLE shall give COMPANY
written notice of any claim(s) related to LICENSED PRODUCT within thirty (30)

                                       18
<PAGE>   8

days, and TEMPLE shall reasonably cooperate with COMPANY and its insurance
carrier in the defense of any such claim(s).

        8.2 In addition to the foregoing, COMPANY shall maintain, during the
period that any LICENSED PRODUCT is sold or otherwise made available to others
pursuant to this Agreement, Commercial Liability Insurance, including Product
Liability Insurance, with a reputable and financially secure insurance carrier()
to cover the activities of COMPANY and its sublicensees, if any, contemplated by
this Agreement for minimum limits of two million dollars ($2,000,000.00) per
occurrence. Such insurance shall name TEMPLE, its trustees, officers, employees,
and agents as additional insureds. COMPANY shall furnish a Certificate of
Insurance, upon request, evidencing coverage of two million dollars
($2,000,000.00) with thirty (30) days of written notice of cancellation or
material change to TEMPLE. COMPANY's insurance shall be written to cover claims
incurred, discovered, manifested, or made during the term, or after the
expiration, of this Agreement. COMPANY shall at all times comply, through
insurance or self-insurance, with all statutory workers' compensation and
employers' liability requirements covering any and all employees with respect to
activities performed under this Agreement.

9.      SUBLICENSEES

        9.1 COMPANY shall have the right to enter into sublicense agreements,
provided that all applicable material terms of this Agreement are incorporated
into such sublicense agreements to provide for the protection of TEMPLE and its
trustees, officers, employees and agents, and provided further that each
sublicensee is required to carry appropriate insurance and indemnify TEMPLE and
COMPANY for claims arising from breach of the sublicense or such sublicensee's
products, and provided further that COMPANY remains primarily liable for its
obligations under this Agreement. A copy of any sublicense agreement shall be
provided to TEMPLE for its review and approval prior to execution, which
approval shall not be unreasonably withheld or delayed. In the event TEMPLE
fails to deliver to COMPANY a written response to a request for approval of a
sublicense under this Agreement within thirty (30) days of the date of the
request, the subject sublicensee shall be automatically approved for all
purposes under this Agreement.

10.     ASSIGNMENT

        10.1 Neither party may assign this Agreement, in whole or in part,
without the written consent of the other, except if such assignment occurs in
connection with the sale of all or substantially all of the business and assets
of the assigning party.

11.     TERMINATION

        11.1 This Agreement may be terminated with respect to any patent
application or patent in any country at any time by mutual written consent of
the parties.

        11.2 COMPANY may, in COMPANY's sole discretion and for any reason
whatsoever, terminate this Agreement in its entirety or only with respect to any
patent application or patent with PATENT RIGHTS in any country by giving TEMPLE
ninety (90) days' prior written notification thereof. In addition, COMPANY may
terminate this Agreement by giving TEMPLE sixty (60) days' prior written notice
upon material breach by TEMPLE of any material provision of this Agreement,
unless such breach is cured within the period of such notice.

                                       19
<PAGE>   9

        11.3 TEMPLE may terminate this Agreement by giving COMPANY three (3)
months' prior written notice upon material breach of any material provision of
this Agreement by COMPANY, unless such breach is cured within the period of such
notice. However, the notice period shall be only thirty (30) days for any breach
by COMPANY for non-payment of moneys due TEMPLE under this Agreement.

        11.4 This Agreement shall immediately terminate, without notice, if
COMPANY breaches the same material provision of this Agreement three (3) times
in the same calendar year, without regard to whether a cure was effected.

        11.5 This Agreement shall immediately terminate if either party is
adjudicated bankrupt, files a voluntary petition in bankruptcy, makes or
executes an assignment for the benefit of creditors, is liquidated or dissolved,
or a receiver, trustee, liquidator, sequestor or other judicial representative
is appointed for either party or its property. In such event, that party shall
execute any documents that are necessary to assign or transfer all interests
granted hereunder.

        11.6 Upon termination of this Agreement, TEMPLE shall have the right to
retain any amounts already paid by COMPANY under this Agreement, and COMPANY
shall pay to TEMPLE all amounts accrued which are then due or which become due
based on the SALE of LICENSED PRODUCT, manufactured or produced prior to the
effective date of termination.

        11.7 The provisions of Article 2 (entitled CONFIDENTIALITY) and Article
8 (entitled INDEMNIFICATION) shall survive the termination of this Agreement.

12.     PATENT MARKING

        12.1 COMPANY agrees to mark or have marked all LICENSED PRODUCT sold by
COMPANY or by its sublicensees under this Agreement in accordance with the
statutes of the United States and countries and territories relating to the
marketing of patented articles in which any LICENSED PRODUCT covered by a
granted patent is marked.

13.     MISCELLANEOUS

        13.1 This Agreement shall be construed and the respective rights of the
parties hereto determined according to the substantive laws of the Commonwealth
of Pennsylvania, notwithstanding the provisions governing conflict of laws under
such Pennsylvania law to the contrary. The parties agree that any dispute
arising out of this Agreement may be resolved by recourse to the courts of the
Commonwealth of Pennsylvania or the United States District Court for the Eastern
District of Pennsylvania.

        13.2 If any provision of this Agreement is held to be invalid or
unenforceable under the laws of any jurisdiction of the parties, all other
provisions shall nevertheless continue in full force and effect.

        13.3 This Agreement constitutes the entire agreement among the parties
pertaining to LICENSED PATENT and supersedes all previous arrangements, whether
written or oral. Any amendment or modification to this Agreement shall be made
in writing signed by both parties.

        13.4 Time is of the essence under this Agreement.

                                       20
<PAGE>   10

        13.5 Notices and payments to the parties shall be addressed as follows:

                      To TEMPLE:       Office of Technology Transfer
                                       Temple University (083-45)
                                       1601 North Broad Street, Room 406
                                       Philadelphia, Pennsylvania 19122-6099

                      To COMPANY:      Nutraceutix, Inc.
                                       Attention:  President
                                       8340 - 154th Ave. N.E.
                                       Redmond, Washington 98052

Either party may change its address for notice by giving notice to the other in
the manner herein provided. Any notice required or provided for by the terms of
this Agreement shall be in writing and sent by registered or certified mail,
return receipt requested, postage prepaid and properly addressed in accordance
with the paragraph above. The effective date of notice shall be the actual date
of receipt.

        IN WITNESS WHEREOF, the parties have caused this Agreement to be
executed by their duly authorized representatives as of the date first written
above.

FOR TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION:

By:  /s/   Martin S. Dorph                     Date:    September 27, 2000
     ------------------------------------            ---------------------------
     Martin S. Dorph
     Vice President, Chief Financial Officer and Treasurer

By:  /s/  David T. Howard                      Date:    June 9, 2000
     ------------------------------------            ---------------------------
     David T. Howard
     President & CEO

                                       21<PAGE>   1
                                                            EXHIBIT 10.1

                              EMPLOYMENT AGREEMENT

               THIS AGREEMENT, dated as of this 18th day of September, 2000, by
and between GETTY IMAGES, INC., a Delaware corporation (the "Company"),
Elizabeth J. Heubner, an individual residing at 14334 155th Avenue NE,
Woodinville, Washington 98072 (the "Employee").

                              W I T N E S S E T H:

               WHEREAS, both parties desire that the terms and conditions of the
Employee's employment with the Company be governed by the terms and conditions
hereinafter set forth.

               NOW, THEREFORE, in consideration of the promises and the mutual
covenants herein contained, the parties hereto hereby agree as follows:

               1. EMPLOYMENT AND DUTIES.

               (a) General. The Company hereby employs the Employee, effective
as of the date hereof (the "Effective Date"), and the Employee agrees upon the
terms and conditions herein set forth to serve, effective as of the Effective
Date, as Senior Vice President & Chief Financial Officer of the Company and
shall perform all duties customarily appurtenant to such position. In such
capacity, the Employee shall report directly to Jonathan Klein, Chief Executive
Officer of the Company, or to such other person designated by the Board of
Directors of the Company. The Employee's principal place of business shall be
Seattle, Washington.

               (b) Services and Duties. For so long as the Employee is employed
by the Company, the Employee shall devote his full business time to the
performance of his duties hereunder; shall faithfully serve the Company; shall
in all respects conform to and comply with the lawful and good faith directions
and instructions given to him by Jonathan Klein, Chief Executive Officer, or
such other person designated by the Board of Directors of the Company; and shall
use his best efforts to promote and serve the interests of the Company.

               (c) No Other Employment. For so long as the Employee is employed
by the Company, he shall not, directly or indirectly, render services to any
other person or organization for which he receives compensation without the
prior approval of Jonathan Klein, Chief Executive Officer, or such other person
designated by the Board of Directors of the Company. No such approval will be
required if the Employee seeks to perform inconsequential services without
direct compensation therefor in connection with the management of personal
investments or in connection with the performance of charitable and civic
activities, provided that such activities do not contravene the provisions of
Section 6 hereof.

               2. TERM OF EMPLOYMENT. The term of the Employee's employment
under this Agreement (the "Term") shall commence on the Effective Date and
continue until it is

                                       1
<PAGE>   2

terminated by either party giving the other at least one month written notice;
provided, however, that in no event may a non-renewal notice be given prior to
October 1, 2001; and provided further, however, that, in any event, the Term
shall not extend beyond the last day of the month in which the Employee attains
age 65.

               3. COMPENSATION AND OTHER BENEFITS. Subject to the provisions of
this Agreement, the Company shall pay and provide the following compensation and
other benefits to the Employee during the Term as compensation for all services
rendered hereunder and the covenants contained in Section 6 hereof:

               (a) Salary. The Company shall pay to the Employee an annual
salary (the "Salary") at the initial rate of $275,000, payable to the Employee
in accordance with the normal payroll practices of the Company for its employees
as are in effect from time to time. The amount of the Employee's Salary shall be
reviewed annually by the Company on or about October 1st of each year during the
Term beginning in the 2001 calendar year. The Company shall pay to the Employee
a one time signing bonus of $27,500 to be paid at the time the Employee receives
his first paycheck from the Company.

               (b) Annual Bonus. The Employee shall be eligible for 2000 and
each calendar year thereafter that begins during his employment to participate
in an annual incentive bonus program established by the Company, in accordance
with the policies of the Company, its subsidiaries and affiliates (hereinafter,
collectively the "Group") and subject to such terms and conditions as may be
approved annually by the Company. Under the terms of the annual incentive bonus
program, the Employee will be afforded the opportunity to earn up to 50% of his
Salary (the "Bonus") in effect for the applicable calendar year, subject to the
achievement of the performance targets established by the Company for that year,
to be paid on a pro-rata basis in the event that the Employee is employed for
less than a full calendar year (for purposes of determining the 2000 bonus, the
Employee shall be deemed to have commenced employment as of October 1, 2000).

               (c) Stock Options. Effective as of the Effective Date, the
Company shall grant the Employee an option (the "Option") to purchase 200,000
shares of the common stock of the Company pursuant to the terms the Company's
1998 Stock Option Plan (the "Option Plan"). The per share exercise price of the
Option shall equal the fair market value of a share of Common Stock on the
Effective Date, as determined in accordance with the terms of the Option Plan.
The Option shall vest and become exercisable as to 25% on October 1, 2001; the
remainder of the Option shall vest ratably on the first day of each month over
the following three years. Except as otherwise specified herein, the Option
shall be subject to the terms of the Option Plan and to such other terms and
conditions as may be specified by the Compensation Committee of the Company in
the form of a standard option agreement between the Company and the Employee.

               Stock Options. The Employee shall be eligible to receive stock
options from time to time, based upon the discretion of the Compensation
Committee of the Company's Board of

                                       2
<PAGE>   3

Directors. Any stock options that are granted to Employee shall be subject to
the terms and conditions of the Company's 1998 Stock Incentive Plan.

               As per the terms of the Company's Option Plan, in the event of a
Change in Control and except as the Committee (as constituted immediately prior
to such Change in Control) may otherwise determine in its sole discretion, (i)
all Stock Options or Stock Appreciation Rights then outstanding shall become
fully exercisable as of the date of the Change in Control, whether or not then
exercisable, (ii) all restrictions and conditions of all Stock Awards then
outstanding shall lapse as of the date of the Change in Control, (iii) all
Performance Share Awards shall be deemed to have been fully earned as of the
date of the Change in Control.

               (d) Expenses. The Company shall pay or reimburse the Employee for
all reasonable out-of-pocket expenses incurred by the Employee in connection
with his employment hereunder in accordance with Group. Such expenses shall be
paid upon the periodic submission of invoices and shall be paid reasonably
promptly after the date of such invoice. The reimbursement of expenses under
this Section 3(d) shall be subject to the Employee's providing the Company with
such documentation of the expenses as the Company may from time to time
reasonably request in accordance with the policies of the Group.

               (e) 401k plan, Health and Fringe Benefits. During the Term, the
Employee shall be eligible to participate in the Company's 401k plan, medical,
disability and life insurance plans applicable to executives of the Company in
accordance with the terms of such plans as in effect from time to time. The
Employee shall also be provided with free parking at the place of employment.

               (f) Long-Term Incentive Program. During the Term, the Employee
shall participate in all long-term incentive plans and programs of the Group
that are applicable to its senior executives in accordance with their terms and
in a manner consistent with his position with the Company.

               (g) Holidays. In addition to the usual public and bank holidays,
the Employee shall be entitled to twenty days' paid vacation annually, which
shall be taken at such times as are approved by the Company. The Employee shall
be permitted to carry forward any portion of his vacation time for up to one
year and, upon the expiration of such one-year period, the Employee shall be
paid in lieu of such vacation days.

               4. TERMINATION OF EMPLOYMENT. Subject to the notice and other
provisions of this Section 4, the Company shall have the right to terminate the
Employee's employment hereunder, and he shall have the right to resign, at any
time for any reason or for no stated reason.

               (a) Termination for Cause; Resignation Without Good Reason. (i)
If, prior to October 1, 2001, the Employee's employment is terminated by the
Company for Cause or if the Employee resigns from his employment hereunder other
than for Good Reason, he shall be

                                       3
<PAGE>   4

entitled to payment of the pro rata portion of his Salary and accrued Bonus (for
purposes of this Agreement, "accrued Bonus" shall be determined using the number
of days in the applicable calendar year that the Employee was employed by the
Company and the applicable performance criteria under the bonus plan, in each
case through the date of termination or resignation) through and including the
date of termination or resignation, as well as any unreimbursed expenses. Except
to the extent required by the terms of any applicable compensation or benefit
plan or program or as otherwise required by applicable law, the Employee shall
have no rights under this Agreement or otherwise to receive any other
compensation or to participate in any other plan, program or arrangement after
such termination or resignation of employment with respect to the year of such
termination or resignation and later years.

               (ii) In addition, the Employee shall be entitled to retain the
then-vested portion of his options to purchase shares of the Company's common
stock until such options expire in accordance with their terms.

               (iii) Termination for "Cause" shall mean termination of the
Employee's employment with the Company because of (A) willful, material or
persistently repeated non-performance of the Employee's duties to the Company
(other than by reason of the incapacity of the Employee due to physical or
mental illness) after notice by the Board of such failure and the Employee's
non-performance and continued, willful, material or persistent repeated
non-performance after such notice, (B) the indictment of the Employee for a
felony offense, (C) fraud against the Group or any willful misconduct that
brings the reputation of the Group into serious disrepute or causes the Employee
to cease to be able to perform his duties, (D) any other material breach by the
Employee of any material term of this Agreement, (E) the Employee files for
personal bankruptcy under the United States Bankruptcy Code, or (F) the Employee
is unable to perform his duties, by reason of disability, for a period of six
(6) months or more.

               (iv) Termination of the Employee's employment for Cause shall be
communicated by delivery to the Employee of a written notice from the Company
stating that the Employee has been terminated for Cause, specifying the
particulars thereof and the effective date of such termination. The date of a
resignation by the Employee without Good Reason shall be the date specified in a
written notice of resignation from the Employee to the Company. The Employee
shall provide at least 30 days' advance written notice of resignation without
Good Reason.

               (b) Involuntary Termination. (i) If, prior to October 1, 2001,
the Company terminates the Employee's employment for any reason other than Cause
or Employee resigns from his employment hereunder for Good Reason (collectively
hereinafter referred to as an "Involuntary Termination"), the Company shall pay
to the Employee his Salary and accrued Bonus up to and including the date of
such Involuntary Termination, as well as any unreimbursed expenses. In addition,
the Company shall continue to pay to the Employee as severance (the "Severance
Payments") in accordance with the Company's normal payroll practices, his
Salary, at the rate in effect immediately prior to such Involuntary Termination,
through and including October 1, 2001.

                                       4
<PAGE>   5

               (ii) In addition, the Employee shall be entitled to retain the
then-vested portion of his options (as of the date of Involuntary Termination)
to purchase shares of the Company's common stock until such options expire in
accordance with their terms

               (iii) Resignation for "Good Reason" shall mean resignation by
Employee because of (A) an adverse and material change in the Employee's duties,
titles or reporting responsibilities, (B) a material breach by the Company of
any term of the Agreement, (C) a reduction in the Employee's Salary or bonus
opportunity or the failure of the Company to pay the Employee any material
amount of compensation when due, (D) the assignment to Employee of any material
duties that are inconsistent with those described in Section 1 of this Agreement
without the Employee's consent, or (E) the Company's requirement that Employee
perform a substantial portion of his duties outside the Seattle, Washington
metropolitan area, except for travel in furtherance of the Company's business.
The Company shall have 30 business days from the date of receipt of such notice
to effect a cure of the material breach described therein and, upon cure thereof
by the Company to the reasonable satisfaction of the Employee, such material
breach shall no longer constitute Good Reason for purposes of this Agreement.

               (iv) The date of termination of employment without Cause shall be
the date specified in a written notice of termination to the Employee. The date
of resignation for Good Reason shall be the date specified in a written notice
of resignation from the Employee to the Company; provided, however, that no such
written notice shall be effective unless the cure period specified in Section
4(b)(iii) above has expired without the Company having corrected, to the
reasonable satisfaction of the Employee, the event or events subject to cure.

               (v) Anything in this Agreement to the contrary notwithstanding,
no amounts shall be payable under this Section 4(b) if the Employee's employment
with the Company ends, for any reason, on or after October 1, 2001.

               5. LIMITATION ON PAYMENTS.

               Notwithstanding anything herein to the contrary, if any of the
payments made hereunder would constitute a "parachute payment" (as defined in
Section 280G(b)(2) of the Internal Revenue Code of 1986, as amended (the
"Code"), and the net after-tax amount of the parachute payment is less than the
net after-tax amount if the aggregate payments to be made to the Employee were
three times his "base amount" (as defined in Section 280G(b)(3) of the Code),
less $1.00, then the aggregate of the amounts constituting the parachute payment
shall be reduced to an amount that will equal three times the base amount, less
$1.00. The determinations to be made with respect to this Section 5 shall be
made by an independent accounting firm of national standing (other than the
Company's regular auditors). The accounting firm shall be paid by the Company
for its services performed hereunder.

                                       5
<PAGE>   6

               6. PROTECTION OF THE COMPANY'S INTERESTS.

               (a) No Competing Employment. For so long as the Employee is
employed by the Company and for one (1) year thereafter (such period being
referred to hereinafter as the "Restricted Period"), the Employee shall not,
without the prior written consent of the Board, directly or indirectly, own an
interest in, manage, operate, join, control, lend money or render financial or
other assistance to or participate in or be connected with, as an officer,
employee, partner, stockholder, consultant or otherwise, any individual,
partnership, firm, corporation or other business organization or entity that
competes with the Group by providing any goods or services provided or under
development by the Group at the effective date of the Employee's termination of
employment under this Agreement; provided, however, that this Section 6(a) shall
not proscribe the Employee's ownership, either directly or indirectly, of either
less than five percent of any class of securities which are listed on a national
securities exchange or quoted on the automated quotation system of the National
Association of Securities Dealers, Inc..

               (b) No Interference. During the Restricted Period, the Employee
shall not, whether for his own account or for the account of any other
individual, partnership, firm, corporation or other business organization (other
than the Company), intentionally solicit, endeavor to entice away from the Group
or otherwise interfere with the relationship of the Group with, any key person
or team who is employed by or otherwise engaged to perform services for the
Group or any key person or team or entity who is, or was within the then most
recent twelve-month period, a customer, client or supplier of the Group.

               (c) Secrecy. The Employee recognizes that the services to be
performed by him hereunder are special, unique and extraordinary in that, by
reason of his employment hereunder, he may acquire confidential information and
trade secrets concerning the operation of the Group, the use or disclosure of
which could cause the Group substantial losses and damages which could not be
readily calculated and for which no remedy at law would be adequate.
Accordingly, the Employee covenants and agrees with the Company that he will not
at any time, except in performance of the Employee's obligations to the Company
hereunder or with the prior written consent of the Board, directly or indirectly
disclose to any person any confidential information that he may learn or has
learned by reason of his association with the Group. The term "confidential
information" means any information not previously disclosed to the public or to
the trade by the Group with respect to the Company's, or any of its affiliates'
or subsidiaries', products, facilities and methods, trade secrets and other
intellectual property, systems, procedures, manuals, confidential reports,
product price lists, customer lists, financial information (including the
revenues, costs or profits associated with any of the Group's products),
business plans, prospects or opportunities.

               (d) Exclusive Property. The Employee confirms that all
confidential information is and shall remain the exclusive property of the
Group. All business records, papers and documents kept or made by the Employee
relating to the business of the Group shall be and remain the property of the
Group. Upon the termination of his employment with the Company or upon the
request of the Company at any time, the Employee shall promptly deliver to the

                                       6
<PAGE>   7

Company, and shall not without the consent of the Board retain copies of, any
written materials not previously made available to the public, or records and
documents made by the Employee or coming into his possession concerning the
business or affairs of the Group; provided, however, that subsequent to any such
termination, the Company shall provide the Employee with copies (the cost of
which shall be borne by the Employee) of any documents which are requested by
the Employee and which the Employee has determined in good faith are (i)
required to establish a defense to a claim that the Employee has not complied
with his duties hereunder or (ii) necessary to the Employee in order to comply
with applicable law.

               (e) Assignment of Developments. All "Developments" (as defined
below) that were or are at any time made, conceived or suggested by Employee,
whether acting alone or in conjunction with others, during Employee's employment
with the Group shall be the sole and absolute property of the Group, free of any
reserved or other rights of any kind on the part of Employee. During Employee's
employment and, if such Developments were made, conceived or suggested by
Employee during his employment with the Group, thereafter, Employee shall
promptly make full disclosure of any such Developments to the Group and, at the
Group's cost and expense, do all acts and things (including, among others, the
execution and delivery under oath of patent and copyright applications and
instruments of assignment) deemed by the Group to be necessary or desirable at
any time in order to effect the full assignment to the Group of Employee's right
and title, if any, to such Developments. For purposes of this Agreement, the
term "Developments" shall mean all data, discoveries, findings, reports,
designs, inventions, improvements, methods, practices, techniques, developments,
programs, concepts, and ideas, whether or not patentable, relating to the
activities of the Group of which Employee is as of the date of this Agreement
aware or of which Employee becomes aware at any time during the Term, excluding
any Development for which no equipment, supplies, facilities or confidential
information of the Group was used and which was developed entirely on Employee's
own time, unless (i) the Development relates directly to the business of the
Group, (ii) the Development relates to actual or demonstrably anticipated
research or development of the Group, or (iii) the Development results from any
work performed by Employee for the Group (the foregoing is agreed to satisfy the
written notice and other requirements of Section 49.44.140 of the Revised Code
of Washington).

               (f) Injunctive Relief. Without intending to limit the remedies
available to the Company, the Employee acknowledges that a breach of any of the
covenants contained in this Section 6 may result in material irreparable injury
to the Group for which there is no adequate remedy at law, that it will not be
possible to measure damages for such injuries precisely and that, in the event
of such a breach or threat thereof, the Company shall be entitled to obtain a
temporary restraining order and/or a preliminary or permanent injunction
restraining the Employee from engaging in activities prohibited by this Section
6 or such other relief as may be required to specifically enforce any of the
covenants in this Section 6. Without intending to limit the remedies available
to the Employee, the Employee shall be entitled to seek specific performance of
the Company's obligations under this Agreement.

               7. GENERAL PROVISIONS.

                                       7
<PAGE>   8

               (a) Source of Payments. All payments provided under this
Agreement, other than payments made pursuant to a plan which provides otherwise,
shall be paid in cash from the general funds of the Company, and no special or
separate fund shall be established, and no other segregation of assets made, to
assure payment. The Employee shall have no right, title or interest whatever in
or to any investments which the Company may make to aid the Company in meeting
its obligations hereunder. To the extent that any person acquires a right to
receive payments from the Company hereunder, such right shall be no greater than
the right of an unsecured creditor of the Company; provided, however, that this
provision shall not be deemed to waive or abrogate any preferential or other
rights to payment accruing to the Employee under applicable bankruptcy laws by
virtue of the Employee's status as an employee of the Company.

               (b) No Other Severance Benefits. Except as specifically set forth
in this Agreement, the Employee covenants and agrees that he shall not be
entitled to any other form of severance benefits from the Company, including,
without limitation, benefits otherwise payable under any of the Company's
regular severance policies, in the event his employment hereunder ends for any
reason and, except with respect to obligations of the Company expressly provided
for herein, the Employee unconditionally releases the Company and its
subsidiaries and affiliates, and their respective directors, officers, employees
and stockholders, or any of them, from any and all claims, liabilities or
obligations under this Agreement or under any severance or termination
arrangements of the Company or any of its subsidiaries or affiliates for
compensation or benefits in connection with his employment or the termination
thereof.

               (c) Tax Withholding. Payments to the Employee of all compensation
contemplated under this Agreement shall be subject to all applicable tax
withholding.

               (d) Notices. Any notice hereunder by either party to the other
shall be given in writing by personal delivery, or certified mail, return
receipt requested, or (if to the Company) by telex or facsimile, in any case
delivered to the applicable address set forth below:

               (i) Getty Images                 701 North 34th Street, Suite 400
                                                Seattle, WA 98103

               (ii) Elizabeth J. Huebner:       14334 155th Avenue NE
                                                Woodinville, WA 98072

or to such other persons or other addresses as either party may specify to the
other in writing.

               (e) Representation by the Employee. The Employee represents and
warrants that his entering into this Agreement does not, and that his
performance under this Agreement and consummation of the transactions
contemplated hereby will not, violate the provisions of any agreement or
instrument to which the Employee is a party, or any decree, judgment or order to
which the Employee is subject, and that this Agreement constitutes a valid and
binding obligation

                                       8
<PAGE>   9

of the Employee in accordance with its terms. Breach of this representation will
render all of the Company's obligations under this Agreement void ab initio.

               (f) Limited Waiver. The waiver by the Company or the Employee of
a violation of any of the provisions of this Agreement, whether express or
implied, shall not operate or be construed as a waiver of any subsequent
violation of any such provision.

               (g) Assignment; Assumption of Agreement. No right, benefit or
interest hereunder shall be subject to assignment, encumbrance, charge, pledge,
hypothecation or setoff by the Employee in respect of any claim, debt,
obligation or similar process. The Company will require any successor (whether
direct or indirect, by purchase, merger, consolidation or otherwise) to all or
substantially all of the business or assets of the Company to assume expressly
and to agree to perform this Agreement in the same manner and to the same extent
that the Company would be required to perform it if no such succession had taken
place.

               (h) Amendment; Actions by the Company. This Agreement may not be
amended, modified or canceled except by written agreement of the Employee and
the Company. Any and all determinations, judgments, reviews, verifications,
adjustments, approvals, consents, waivers or other actions of the Company
required or permitted under this Agreement shall be effective only if undertaken
by the Company pursuant to authority granted by a resolution duly adopted by the
Board; provided, however, that by resolution duly adopted in accordance with
this Section 7(h), the Board may delegate its responsibilities hereunder to one
or more of its members other than the Employee.

               (i) Severability. If any term or provision hereof is determined
to be invalid or unenforceable in a final court or arbitration proceeding, (i)
the remaining terms and provisions hereof shall be unimpaired and (ii) the
invalid or unenforceable term or provision shall be deemed replaced by a term or
provision that is valid and enforceable and that comes closest to expressing the
intention of the invalid or unenforceable term or provision.

               (j) Governing Law. This Agreement shall be governed by and
construed in accordance with the laws of the State of Delaware (determined
without regard to the choice of law provisions thereof).

               (k) Entire Agreement. This Agreement sets forth the entire
agreement and understanding of the parties hereto with respect to the matters
covered hereby and supersedes all prior agreements and understandings of the
parties with respect to the subject matter hereof.

               (l) Headings. The headings and captions of the sections of this
Agreement are included solely for convenience of reference and shall not control
the meaning or interpretation of any provisions of this Agreement.

                                       9
<PAGE>   10

               (m) Counterparts. This Agreement may be executed by the parties
hereto in counterparts, each of which shall be deemed an original, but both such
counterparts shall together constitute one and the same document.

               (n) Disciplinary and Grievance Procedures. For statutory
purposes, there is no formal disciplinary procedure in relation to the
Employee's employment. The Employee shall be expected to maintain the highest
standards of integrity and behavior. If the Employee has any grievance in
relation to his employment or is not satisfied with any disciplinary procedure
taken in relation to him, he may apply in writing within 14 days of that
decision to the Board, whose decision shall be final. The foregoing shall not be
construed, however, to limit the Employee's remedies at law or otherwise.

               IN WITNESS WHEREOF, the parties have executed this Agreement
effective as of the day and year first written above.

                                    GETTY IMAGES, INC.

                                    By:
                                       -----------------------------------------
                                    Name: Jonathan Klein
                                         ---------------------------------------
                                    Title: Chief Executive Officer
                                          --------------------------------------
                                    Date:
                                         ---------------------------------------

                                    EMPLOYEE

                                    By:
                                       -----------------------------------------
                                    Name:
                                         ---------------------------------------
                                    Date:
                                         ---------------------------------------

                                       10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00017-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00017-of-00352.parquet"}]]